Equities

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)34.70
  • Today's Change0.17 / 0.49%
  • Shares traded10.22m
  • 1 Year change+14.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,0182,7522,768
Total Receivables, Net2,7232,8212,084
Total Inventory1,5671,4291,525
Prepaid expenses767249
Other current assets, total169171--
Total current assets6,5527,2456,425
Property, plant & equipment, net1,4921,5041,521
Goodwill, net6685--
Intangibles, net331292203
Long term investments1,518816756
Note receivable - long term------
Other long term assets------
Total assets10,23010,1579,067
LIABILITIES
Accounts payable615724599
Accrued expenses337305163
Notes payable/short-term debt707913735
Current portion long-term debt/capital leases3.564.1032
Other current liabilities, total1,5711,387906
Total current liabilities3,2333,3332,434
Total long term debt2441521.57
Total debt9541,069768
Deferred income tax7.338.824.21
Minority interest4530149
Other liabilities, total101111114
Total liabilities3,6293,6362,703
SHAREHOLDERS EQUITY
Common stock770773773
Additional paid-in capital9751,0481,374
Retained earnings (accumulated deficit)4,8284,7004,218
Treasury stock - common(7.04)(30)(32)
Unrealized gain (loss)343031
Other equity, total------
Total equity6,6016,5216,364
Total liabilities & shareholders' equity10,23010,1579,067
Total common shares outstanding769769769
Treasury shares - common primary issue1.294.574.57
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.